GlassScriptPhysician profile
John L Burkard
NPI 1730187618
$11,092.08
in general payments reported to CMS, 2019-2025
47 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $1,365 · 2021: $1,978 · 2022: $2,041 · 2023: $1,596 · 2024: $1,518 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089 · Education: $90.00 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.28 |
| Education | $90.00 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,684.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,021.48 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $871.94 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $781.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $736.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $724.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $528.59 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.73 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $369.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $344.49 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $316.98 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $287.42 | 2019-2024 | Livalo |
| Astellas Pharma US INC | $259.95 | 2022-2024 | Veozah, Myrbetriq |
| Resmed Corp | $250.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $237.45 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $235.91 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $224.94 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Genzyme Corporation | $195.00 | 2019 | |
| Abbott Laboratories | $183.71 | 2021-2025 | Proclaim, Freestyle Libre 3, Lamitrode |
| Teva Pharmaceuticals USA, INC. | $158.22 | 2020-2023 | Ajovy |
| Amarin Pharma, INC. | $150.26 | 2019-2021 | |
| Daiichi Sankyo INC. | $95.53 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.51 | 2022 | |
| Eisai INC. | $67.51 | 2021-2022 | |
| Exact Sciences Corporation | $62.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $61.44 | 2021 | |
| Allergan, INC. | $61.12 | 2020 | |
| Medtronic, INC. | $54.34 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.40 | 2019-2023 | Xifaxan, Trulance |
| Boston Scientific Corporation | $50.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $46.01 | 2022-2023 | Quviviq |
| Organogenesis INC. | $42.81 | 2022 | |
| Gilead Sciences, INC. | $42.69 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $42.00 | 2020 | |
| Sanofi Pasteur INC. | $38.96 | 2025 | |
| Currax Pharmaceuticals LLC | $30.70 | 2020-2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.29 | 2022 | |
| Dexcom, INC. | $24.81 | 2023 | Dexcom G6 Transmitter |
| Sonex Health, INC. | $20.00 | 2025 | Sx-One Microknife |
| Azurity Pharmaceuticals, INC. | $18.81 | 2023 | Edarbi |
| Vbi Vaccine (Delaware) INC. | $18.72 | 2023 | Prehevbrio |
| Viiv Healthcare Company | $15.60 | 2025 | Apretude |
| Insulet Corporation | $15.26 | 2025 | Omnipod |
| Bausch Health US, LLC | $15.04 | 2019 | |
| Medicure Pharma INC. | $12.16 | 2019 | |
| Lucid Diagnostics INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burkard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.